Curium Announces Definitive Agreement to Merge with Lantheus
· Financial Post
BOSTON and BEDFORD, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Curium™, a leading, global radiopharmaceutical company with proven expertise in the development, manufacturing and supply of radiopharmaceuticals that improve the way cancer is diagnosed and treated, and Lantheus Holdings, Inc. ("Lantheus" or "Company") (NASDAQ: LNTH), today announced that Curium US Holdings LLC (“Curium US”) and Lantheus have entered into a definitive agreement under which Lantheus, a leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, will merge with a wholly-owned subsidiary of Curium US. Read More
Visit mchezo.life for more information.